{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:28:30Z","timestamp":1790180910764,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1097\/cji.0b013e3181bfcea1","type":"journal-article","created":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T02:26:34Z","timestamp":1266373594000},"page":"178-184","source":"Crossref","is-referenced-by-count":10,"title":["A Phase 2 Trial of Immunotherapy With Mitumprotimut-T (Id-KLH) and GM-CSF Following Rituximab in Follicular B-cell Lymphoma"],"prefix":"10.1097","volume":"33","author":[{"given":"Omer N.","family":"Ko\u00e7","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Wiernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Rosenfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan P.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Ghalie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210227","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors","volume":"327","author":"Kwak","year":"1992","journal-title":"N Engl J Med"},{"key":"R2-7-20210227","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","article-title":"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial","volume":"89","author":"Hsu","year":"1997","journal-title":"Blood"},{"key":"R3-7-20210227","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat Med"},{"key":"R4-7-20210227","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0022-2011(94)90400-6","article-title":"A new insect cell line from Trichoplusia ni (BTI-Tn-5B1-4) susceptible to Trichoplusia ni single enveloped nuclear polyhedrosis virus","volume":"64","author":"Granados","year":"1994","journal-title":"J Invert Path"},{"key":"R5-7-20210227","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2005.04.4289","article-title":"Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses","volume":"19","author":"Redfern","year":"2006","journal-title":"J Clin Oncol"},{"key":"R6-7-20210227","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"R7-7-20210227","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat Med"},{"key":"R8-7-20210227","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.V106.11.2438.2438","article-title":"Long-term follow-up of patients treated in a phase 2 trial with MyVax\u00ae personalized immunotherapy (recombinant Id-KLH with GM-CSF) after chemotherapy as initial treatment for follicular Non-Hodgkin's lymphoma (NHL)","volume":"106","author":"Timmerman","year":"2005","journal-title":"Blood"},{"key":"R9-7-20210227","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1200\/jco.2006.24.18_suppl.7529","article-title":"Preliminary immune response (IR) results of a phase 2 study with idiotype (Id) immunotherapy after treatment with CVP and rituximab for follicular non-Hodgkin's lymphoma (FL)","volume":"24","author":"Leonard","year":"2006","journal-title":"J Clin Oncol"},{"key":"R10-7-20210227","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood.V110.11.4500.4500","article-title":"BiovaxID vaccine therapy of follicular lymphoma in first remission: phase III blinded safety update","volume":"110","author":"Stergiou","year":"2007","journal-title":"Blood"},{"key":"R11-7-20210227","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R12-7-20210227","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of Yttrium-90-labeled ibritumomab tioxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"R13-7-20210227","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"R14-7-20210227","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002770000163","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group","volume":"79","author":"Feuring-Buske","year":"2000","journal-title":"Ann Hematol"},{"key":"R15-7-20210227","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage follicular grade I non-Hodgkin's lymphoma: a Phase II Trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"R16-7-20210227","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up of 7 years","volume":"108","author":"Colombat","year":"2006","journal-title":"Blood"},{"key":"R17-7-20210227","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab significantly increases event-free survival and response duration compared with the standard weekly x4 schedule","volume":"103","author":"Ghelmini","year":"2004","journal-title":"Blood"},{"key":"R18-7-20210227","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/djj358","article-title":"Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma","volume":"98","author":"Inoges","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"R19-7-20210227","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1182\/blood.V108.11.2756.2756","article-title":"Phase III trial of active immunotherapy (FavId\u00ae, Id\/KLH) following rituximab induction therapy: clinical responses in patients with follicular non-Hodgkin's lymphoma","volume":"108","author":"Freedman","year":"2006","journal-title":"Blood"},{"key":"R20-7-20210227","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood.V112.11.236.236","article-title":"placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in patients with CD20+ follicular lymphoma","volume":"112","author":"Freedman","year":"2008","journal-title":"Blood"},{"key":"R22-7-20210227","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa041109","article-title":"Sargramostim for active Crohn's disease","volume":"352","author":"Korzenik","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CJI.0b013e3181bfcea1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:13:47Z","timestamp":1786040027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002371-201002000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e3181bfcea1","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}